Citation:Bhargava R,Kumar P,Kumar M,Mehra N,Mishra A.A randomized controlled trial of omega-3 fatty acids in dry eye syndrome.Int J Ophthalmol 2013;6(6):811-816,doi:10.3980/j.issn.2222-3959.2013.06.13
A randomized controlled trial of omega-3 fatty acids in dry eye syndrome
Received:July 17, 2013  Revised:August 16, 2013
Email this Article  Add to Favorites  Print
DOI:10.3980/j.issn.2222-3959.2013.06.13
Key Words:dry eye syndrome; omega-3 fatty acids; conjunctival impression cytology; meibomian gland disease
Fund Project:
              
AuthorInstitution
Rahul Bhargava Department of Ophthalmology, Santosh Medical College and Hospital, Ghaziabad , India
Prachi Kumar Department of Pathology, Santosh medical College and Hospital, Ghaziabad , India
Manjushrii Kumar Department of Microbiology, Narayan Medical College and Hospital, Sasaram , India
Namrata Mehra Department of Ophthalmology, Santosh Medical College and Hospital, Ghaziabad , India
Anurag Mishra Department of Ophthalmology, Santosh Medical College and Hospital, Ghaziabad , India
Hits: 2333
Download times: 205
Abstract:
      AIM: To evaluate the role of dietary supplementation of omega-3 fatty acids in dry eye syndrome.

    METHODS: A prospective, interventional, placebo controlled, double blind randomized trial was done at two referral eye centers. Two hundred and sixty-four eyes of patients with dry eye were randomized to receive one capsule (500mg) two times a day containing 325mg EPA and 175mg DHA for 3 months (omega-3 group). The omega-3 group was compared to a group of patients (n=254) who received a placebo (placebo group). There were 4 patient visits (at baseline, 1 month, 2 months and 3 months). On each visit, recording of corrected distance visual acuity (CDVA), slit lamp examination and questionnaire based symptom evaluation and scoring was done. A symptomatic score of 0-6 was mild, 6.1-12 moderate and 12.1-18 severe dry eye. Response to intervention was monitored by routine tear function tests like Schirmer I test, tear film break-up time (TBUT), Rose Bengal staining and most notably, conjunctival impression cytology.

    RESULTS: Sixty-five percent of patients in the omega-3 group and 33% of patients in placebo group had significant improvement in symptoms at 3 months (P=0.005). There was a significant change in both Schirmer’s test value and TBUT values in the omega-3 group (P<0.001), both comparisons. However, there was a larger drift in TBUT values in omega-3 than the placebo group, in comparison to Schirmer’s test values. The mean TBUT score was 2.54±2.34 in the omega-3 group and 0.13±0.16 in placebo group, respectively. The mean reduction in symptom score in omega-3 group was 2.02±0.96 as compared to 0.48±0.22 in placebo group (P<0.001). Despite a slight increase mean score, the Schirmer scores did not correlate well with symptomatic improvement.

    CONCLUSION: Omega-3 fatty acids have a definite role for dry eye syndrome. The benefit seems to be more marked in conditions such as blepharitis and meibomian gland disease. The role of omega fatty acids in tear production and secretion needs further evaluation.

PMC FullText Html:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874521/
PDF Fulltext  Download reader  HTML Fulltext   View/Add Comment